Several studies proposed that the increase in IL-4 expression mediates the action of acetylcholinesterase inhibitors in AD patients (Gambi et al. 2004; Reale et al. 2004), suggesting that this interleukin has an immunomodulatory role in AD (Fig. 3). Here, IL4 is linked to Alzheimer disease.